Down syndrome may hold key to new Alzheimer's treatments






Down syndrome may hold key to new Alzheimer's treatments



CHICAGO (Reuters) - In a new lead on Alzheimer's research, Johnson & Johnson is bankrolling a three-year pilot study of people with Down syndrome to identify the early changes that herald dementia, which afflicts up to 75 percent of adults with the condition. The aim is to generate support for a much bigger, public-private partnership funded by drugmakers, advocates and government agencies that will study at least 1,000 people with Down syndrome, tracking them from an early age and eventually testing treatments to keep dementia from developing. ...






Popular posts from this blog

One dead, more than dozen hurt as storm rips through baseball party tent

Which Wedding Style Is The Best Fit For A Couple?

Greece opens detention camp for immigrants as election looms